BOK Financial’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $890K | Sell |
20,845
-5,573
| -21% | -$303K | 0.01% | 453 |
|
|
2026
Q1 | $1.66M | Sell |
26,418
-4,273
| -14% | -$342K | 0.03% | 351 |
|
|
2025
Q4 | $2.93M | Buy |
30,691
+2,630
| +9% | +$258K | 0.04% | 270 |
|
|
2025
Q3 | $2.74M | Buy |
28,061
+22,930
| +447% | +$2.37M | 0.04% | 294 |
|
|
2025
Q2 | $551K | Sell |
5,131
-1,940
| -27% | -$196K | 0.01% | 543 |
|
|
2025
Q1 | $713K | Sell |
7,071
-386
| -5% | -$38.9K | 0.01% | 483 |
|
|
2024
Q4 | $708K | Buy |
7,457
+84
| +1% | +$7.39K | 0.01% | 488 |
|
|
2024
Q3 | $618K | Buy |
7,373
+4,308
| +141% | +$340K | 0.01% | 521 |
|
|
2024
Q2 | $236K | Buy |
3,065
+377
| +14% | +$27.6K | ﹤0.01% | 740 |
|
|
2024
Q1 | $183K | Sell |
2,688
-434
| -14% | -$27.9K | ﹤0.01% | 730 |
|
|
2023
Q4 | $180K | Buy |
3,122
+876
| +39% | +$46.8K | ﹤0.01% | 674 |
|
|
2023
Q3 | $115K | Sell |
2,246
-14,568
| -87% | -$764K | ﹤0.01% | 692 |
|
|
2023
Q2 | $909K | Sell |
16,814
-378
| -2% | -$19.7K | 0.02% | 474 |
|
|
2023
Q1 | $860K | Sell |
17,192
-17,840
| -51% | -$841K | 0.02% | 482 |
|
|
2022
Q4 | $1.62M | Buy |
35,032
+2,490
| +8% | +$108K | 0.03% | 405 |
|
|
2022
Q3 | $1.26M | Sell |
32,542
-9,908
| -23% | -$397K | 0.03% | 453 |
|
|
2022
Q2 | $1.58M | Sell |
42,450
-588
| -1% | -$23.9K | 0.03% | 425 |
|
|
2022
Q1 | $1.91M | Buy |
43,038
+4,581
| +12% | +$199K | 0.03% | 427 |
|
|
2021
Q4 | $1.63M | Sell |
38,457
-6,573
| -15% | -$276K | 0.03% | 460 |
|
|
2021
Q3 | $1.95M | Buy |
+45,030
| New | +$1.99M | 0.03% | 401 |
|
|
2021
Q1 | $905K | Sell |
23,407
-14,222
| -38% | -$538K | 0.02% | 575 |
|
|
2020
Q4 | $1.35M | Buy |
37,629
+18,642
| +98% | +$672K | 0.03% | 450 |
|
|
2020
Q3 | $725K | Buy |
18,987
+176
| +0.9% | +$6.78K | 0.02% | 534 |
|
|
2020
Q2 | $661K | Sell |
18,811
-1,553
| -8% | -$55.9K | 0.02% | 549 |
|
|
2020
Q1 | $664K | Buy |
20,364
+484
| +2% | +$18.9K | 0.02% | 506 |
|
|
2019
Q4 | $899K | Sell |
19,880
-9,523
| -32% | -$398K | 0.02% | 537 |
|
|
2019
Q3 | $1.2M | Buy |
29,403
+12,082
| +70% | +$512K | 0.03% | 452 |
|
|
2019
Q2 | $744K | Buy |
17,321
+9,204
| +113% | +$354K | 0.02% | 561 |
|
|
2019
Q1 | $311K | Buy |
8,117
+800
| +11% | +$30.6K | 0.01% | 773 |
|
|
2018
Q4 | $259K | Buy |
7,317
+1,338
| +22% | +$48.5K | 0.01% | 766 |
|
|
2018
Q3 | $231K | Buy |
+5,979
| New | +$209K | 0.01% | 850 |
|
Other funds holding BSX
BOK Financial's BSX Position: Q2 2026 in Review
BOK Financial reduced its Boston Scientific (BSX) stake by 21% in Q2 2026, selling an estimated $303K and leaving 20,845 shares worth $890K. The position accounts for 0.01% of the portfolio, ranked #453.
BOK Financial first reported a position in BSX in Q3 2018 and has held it in 31 quarters since. The position peaked at $2.93M in Q4 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- BOK Financial held 20,845 shares of Boston Scientific worth $890K as of Q2 2026.
- BOK Financial sold 5,573 Boston Scientific shares in Q2 2026, an estimated $303K.
- Boston Scientific made up 0.01% of BOK Financial's portfolio in Q2 2026, its #453 holding.
- BOK Financial first reported a position in Boston Scientific in Q3 2018 and has held it in 31 quarters since.
- BOK Financial's Boston Scientific position peaked at $2.93M in Q4 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.